Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE4.3700
- TODAY'S CHANGE (%)0.0800 (1.8648%)
- Bid / Lots4.3600/ 4
- Ask / Lots4.3700/ 51
- Open / Previous Close4.3000 / 4.2900
- Day Range
- 52 Week Range
- Volume243,862
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 10909 | 4.29 |
| 09:36 ET | 940 | 4.27 |
| 09:38 ET | 100 | 4.27 |
| 09:41 ET | 1400 | 4.26 |
| 09:43 ET | 100 | 4.26 |
| 09:45 ET | 600 | 4.27 |
| 09:50 ET | 13539 | 4.261 |
| 09:52 ET | 1444 | 4.305 |
| 09:54 ET | 13878 | 4.335 |
| 09:56 ET | 6995 | 4.33 |
| 09:57 ET | 8006 | 4.35 |
| 09:59 ET | 1700 | 4.33 |
| 10:01 ET | 700 | 4.32 |
| 10:03 ET | 543 | 4.33 |
| 10:06 ET | 550 | 4.35 |
| 10:08 ET | 998 | 4.35 |
| 10:10 ET | 2011 | 4.345 |
| 10:12 ET | 2700 | 4.35 |
| 10:14 ET | 1437 | 4.35 |
| 10:15 ET | 8000 | 4.33 |
| 10:17 ET | 2000 | 4.33 |
| 10:21 ET | 300 | 4.325 |
| 10:24 ET | 700 | 4.32 |
| 10:28 ET | 100 | 4.315 |
| 10:30 ET | 3969 | 4.325 |
| 10:32 ET | 5394 | 4.295 |
| 10:33 ET | 350 | 4.3 |
| 10:37 ET | 30629 | 4.31 |
| 10:42 ET | 2447 | 4.27 |
| 10:44 ET | 4595 | 4.25 |
| 10:46 ET | 1772 | 4.27 |
| 10:48 ET | 2266 | 4.275 |
| 10:50 ET | 790 | 4.28 |
| 10:51 ET | 200 | 4.28 |
| 10:55 ET | 610 | 4.28 |
| 11:00 ET | 1199 | 4.28 |
| 11:02 ET | 2795 | 4.29 |
| 11:04 ET | 1300 | 4.29 |
| 11:06 ET | 700 | 4.305 |
| 11:08 ET | 805 | 4.315 |
| 11:09 ET | 1700 | 4.3189 |
| 11:11 ET | 100 | 4.315 |
| 11:24 ET | 6004 | 4.335 |
| 11:26 ET | 1140 | 4.33 |
| 11:27 ET | 1900 | 4.33 |
| 11:31 ET | 500 | 4.3222 |
| 11:36 ET | 882 | 4.3391 |
| 11:40 ET | 200 | 4.34 |
| 11:42 ET | 619 | 4.34 |
| 11:44 ET | 892 | 4.35 |
| 11:45 ET | 1300 | 4.35 |
| 11:47 ET | 1532 | 4.35 |
| 11:49 ET | 1411 | 4.345 |
| 11:51 ET | 300 | 4.35 |
| 11:54 ET | 8434 | 4.34 |
| 11:58 ET | 400 | 4.35 |
| 12:03 ET | 3619 | 4.34 |
| 12:09 ET | 1973 | 4.35 |
| 12:12 ET | 100 | 4.35 |
| 12:14 ET | 29613 | 4.38 |
| 12:16 ET | 1200 | 4.38 |
| 12:18 ET | 10874 | 4.37 |
| 12:21 ET | 350 | 4.365 |
| 12:23 ET | 8947 | 4.37 |
Oct 1, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 8:47AM ET on Tuesday Oct 01, 2024 by Dow Jones
8:47AM ET on Tuesday Oct 01, 2024 by Dow Jones
Sep 17, 2024
DJ Mereo BioPharma Group Down Over 9%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk, from 1:42PM ET on Tuesday Sep 17, 2024 by Dow Jones
1:42PM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 16, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 12:21PM ET on Monday Sep 16, 2024 by Dow Jones
12:21PM ET on Monday Sep 16, 2024 by Dow Jones
Sep 12, 2024
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference, from 5:35PM ET on Thursday Sep 12, 2024 by Dow Jones
5:35PM ET on Thursday Sep 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 660.0M | -13.3x | --- |
Immunome Inc | 810.7M | -2.4x | --- |
Perspective Therapeutics Inc | 890.7M | -9.5x | --- |
Oruka Therapeutics Inc | 875.0M | -4.2x | --- |
IGM Biosciences Inc | 854.2M | -3.9x | --- |
Applied Therapeutics Inc | 963.6M | -5.2x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $660.0M |
|---|---|
Revenue (TTM) | $10.5M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-0.33 |
Book Value | $0.47 |
P/E Ratio | -13.3x |
Price/Sales (TTM) | 62.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
